Breast cancer: Microproteins essential for cancer growth

In women, breast cancer is the most common cancer. One in eight women suffers from a malignant tumor in her breast during her life. The type of breast cancer is crucial for prognosis and therapy. Depending on certain receptors on the surface of the cancer cells, the tumors are divided into two groups: hormone receptor positive and hormone receptor negative breast cancer. Most tumors of the breast are hormone receptor-positive, the cancer cells carry on their surface receptors for the sex hormones estrogen and progesterone.

"Although the group of hormone receptor-positive tumors has a better prognosis than other breast cancers, they are responsible for many deaths simply because of their frequency," explains Sven Diederichs of the German Cancer Research Center. "To find new ways to treat breast cancer, we first need to understand exactly how the tumor cells work. So far, our knowledge about the development and progression of the disease is not enough to treat it optimally, "he emphasizes.

Diederichs and his team compared breast cancer cells with breast tissue cells of healthy women. They found that a particular microprotein was much more common in breast cancer cells than in normal cells.

Microproteins have not been known for a long time. To produce a microprotein, the cell reads genetic material that has long been thought to contain no protein instructions. "Molecular biology databases are teeming with these supposedly noncoding RNA molecules, which are sometimes used by the cells to produce small proteins," Diederichs says.

In recent years, microproteins have been found to play a role in muscle development and cardiovascular disease. The microprotein CASIMO1, which was discovered by the DKFZ researchers and consists of just 83 amino acids, is the first to show any function in cancer.

CASIMO1 is present in breast cancer cells, especially of hormone receptor-positive tumors, in high concentration. The underlying gene is used extensively for protein production. In experiments on cell cultures, the scientists around Diederichs switched off the CASIMO1 gene. This demonstrated the importance of CASIMO1 for the survival of breast cancer cells: The lack of the microprotein interrupted the cell cycle of the breast cancer cells and thus inhibited their growth.

Next, the DKFZ scientists want to examine other microproteins that they have already found in patients with breast cancer or lung cancer. "The long-term hope is to be able to use these small proteins as therapeutic targets and to inhibit them with drugs," says Diederichs.

Maria Polycarpou-Schwarz, Matthias Groß, Pieter Mestdagh, Johanna Schott, Stefanie E. Grund, Catherina Hildenbrand, Joachim Rom, Sebastian Aulmann, Hans-Peter Sinn, Jo Vandesompele, Sven Diederichs. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene (2018), DOI: 10.1038/s41388-018-0281-5

A picture is available for download:
https://www.dkfz.de/de/presse/pressemitteilungen/2018/bilder/merged-ORF-scalebar.tif

Picture Caption: The breast cancer cell line MCF7 produces the microprotein CASIMO1 (green). Shown in red is the cytoskeleton protein actin, the cell nuclei appear blue.

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: M. Polycarpou-Schwarz; S. Diederichs, DKFZ”.

Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.